Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early...
Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C. The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022. Star’s biotech startups Vega Therapeutics and Electra Therapeutics...
Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven...
SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...
© 2023 STAR Therapeutics Inc.
We look forward to connecting with you
